J
Joachim von Pawel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 144
Citations - 27028
Joachim von Pawel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 142 publications receiving 25012 citations.
Papers
More filters
Journal ArticleDOI
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Frank Breitenbuecher,Joachim von Pawel,Martin Sebastian,Cornelius Kortsik,Saskia Ting,Stefan Kasper,J. Wohlschläger,Karl Worm,Alicia Morresi-Hauf,Arno Schad,Daniela Westerwick,Beatrice Wehler,Martin Werner,Gerd Munzert,Birgit Gaschler-Markefski,Kurt Werner Schmid,Martin Schuler +16 more
TL;DR: This hypothesis-generating study in BI2531-treated patients could not establish a correlation between KRAS mutations and relevant clinical endpoints, and future clinical trials with concomitant systematic biosampling and comprehensive molecular analyses are required to identify biomarkers predictive for response to PLK1 inhibitors.
Journal ArticleDOI
C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP)
Ulrich Gatzemeier,Paul D. Taylor,Joachim von Pawel,B. Castagneto,Graham Dark,M. Marangolo,Rob J. van Klaveren,Jan P. van Meerbeeck,S. Adachi,J. Blatter +9 more
Journal ArticleDOI
C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)
Martin Reck,Joachim von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,Vera Hirsh,Natasha B. Leighl,J. Mezger,V. Archer,Christian Manegold +9 more
Journal ArticleDOI
O-59 Quality of life with single agent oral topotecan vs intravenous topotecan in patients with chemosensitive small cell lung cancer (SCLC). An international phase III study
Journal ArticleDOI
Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.
Nikolaus A Handke,Alexander Rupp,Alexander Rupp,Nicolai Trimpop,Joachim von Pawel,Stefan Holdenrieder,Stefan Holdenrieder +6 more
TL;DR: In this paper, the authors investigated the relevance of soluble high mobility group box 1 protein (HMGB1) for the prediction and monitoring of therapy response as well as the estimation of prognosis in advanced lung cancer.